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ABSTRACT
Triple antiplatelet therapy has been known to be superior to the conventional dual regimen for preventing stent thrombosis 
after coronary stenting, and the addition of oral anticoagulation to antiplatelet therapy is also considered an option. Howev-
er, the risks and benefits of a triple antiplatelet regimen plus additional oral anticoagulation must be taken into account. Here, 
we report a case of fatal renal bleeding in a patient treated with triple antiplatelet plus oral anticoagulant therapy for the pre-
vention of recurrent stent thrombosis. (Korean Circ J 2010;40:348-351)
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Introduction
Stent thrombosis is a troublesome complication of coro-
nary stenting, and its optimal treatment still needs to be de-
termined. Triple antiplatelet therapy has recently been re-
ported to be superior to the conventional dual regimen for 
preventing stent thrombosis. The addition of oral anticoagu-
lation to antiplatelet therapy can be considered for patients 
with recurrent stent thrombosis. However, the benefit of ad-
ditional warfarin therapy to antiplatelet therapy has not been 
widely evaluated. Furthermore, potential bleeding after ad-
ditional anticoagulation can result in lethal complications.
Here, we report a case of fatal renal bleeding in a patient 
treated with triple antiplatelet plus oral anticoagulant therapy 
for the prevention of recurrent stent thrombosis. The possi-
ble benefits and risks of aggressive antithrombotic strategies 
after percutaneous coronary intervention (PCI) are also dis-
cussed. 
Case 
A 54-year-old man was admitted to our hospital in Novem-
ber 2008 because of flank pain lasting 2 hours. Since 1998, the 
patient had been treated with peritoneal dialysis for end-stage 
renal disease associated with polycystic kidney disease (PKD). 
In 2003, he underwent the first PCI, in which 2 drug-eluting 
stents (DES) (Taxus 3.5×16 mm and Taxus 3.5×28 mm, Bos-
ton Scientific, Natick, MA, USA) were implanted in the right 
coronary artery (RCA). Aspirin (100 mg once daily) and clopi-
dogrel (75 mg once daily) were prescribed thereafter. 
In July 2008, he experienced sudden chest pain. Coronary 
angiography revealed near total occlusion of the RCA due to 
stent thrombosis (Fig. 1A). A de novo lesion in the proximal 
part of the RCA was also noted. The thrombus was removed 
by a suction catheter and two more DESs (Cypher 3.5×28 
mm and Cypher 3.5×33 mm, Cordis, Miami, FL, USA) were 
implanted in the RCA (Fig. 1B). Cilostazol (100 mg twice da-
ily) was added to the dual antiplatelet regimen. In August 2008, 
the patient was readmitted for unstable angina. Coronary an-
giography showed a recurrent stent thrombosis (Fig. 1C) and 
the patient was treated with thrombosuction (Fig. 1D). Aspi-
rin and clopidogrel resistance test (VeryfyNow, Accumetics 
Inc., San Diego, CA, USA) results were negative. Also, no evi-
dence of other thrombophilic risk factors such as heparin-in-
duced thrombocytopenia or patient malcompliance was found. 
Warfarin was added to the triple antiplatelet therapy. The pro-
thrombin time/international normalized ratio (PT/INR) was Jeonggeun Moon, et al.   349
maintained at 2.0 to 3.0. However, the patient was readmitted 
for recurrent chest pain in September 2008. Coronary angiog-
raphy again revealed a recurrent stent thrombosis (Fig. 1E). Af-
ter repeated thrombosuction, a bare-metal stent (Vision 3.5× 
23 mm, Guidant, Temecula, CA, USA) was implanted to cover 
the lesion (Fig. 1F). 
In November 2008, the patient visited the emergency room 
complaining of severe left flank pain. His blood pressure was 
90/60 mmHg, and laboratory tests revealed a hematocrit of 
26.4% and a PT/INR of 2.7. Abdominal computed tomogra-
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Fig. 1. Coronary angiographies taken at each event (RCA). A: stent thrombosis and partial obstruction in the RCA (arrow) in July 2008. B: 
RCA revascularized by thrombosuction and implantation of new stents. C: recurrent stent thrombosis and partial obstruction (arrow) in Au-
gust 2008. D: lesion revascularized by thrombosuction. E: recurrent stent obstruction (arrow) in September 2008. F: lesion treated by re-
peated thrombosuction and new stent implantation. 350   Fatal Renal Bleeding After Aggressive Antithrombotic Therapy
phy revealed significant hemorrhage in the left kidney (Fig. 2). 
An urgent percutaneous embolization of the renal artery failed 
to stop the bleeding. Although an emergency nephrectomy 
was performed, disseminated intravascular coagulopathy and 
metabolic acidosis developed and continued unabated after 
surgery. On hospital day 3, the patient died of multiple organ 
failure. 
Discussion
Stent thrombosis is a troublesome complication of PCI. It 
is often disastrous and is associated with high mortality rates 
ranging from 20% to 25%.
1) In addition, an effective and ap-
propriate strategy for managing stent thrombosis has not been 
firmly established.
Premature discontinuation of dual antiplatelet therapy is a 
well-known cause of stent thrombosis. However, the occur-
rence of stent thrombosis despite adherence to the drug regi-
men suggests that some patients are unresponsive to clopidog-
rel therapy. Unresponsiveness is essentially caused by func-
tional and genetic variations in cytochrome P450 enzymes.
2) 
In addition, chronic kidney disease, diabetes mellitus, reduced 
ventricular systolic function, acute coronary syndrome, im-
paired flow restoration, total occlusions, long stent length, and 
a number of treated lesions are reported as predictors for stent 
thrombosis.
3-5) Our patient had several risk factors for stent 
thrombosis, including end-stage renal disease and long lesion 
length, whereas he was not resistant to aspirin or clopidogrel, 
and had good compliance with antiplatelet agents. 
Triple antiplatelet therapy was prescribed for our patient. In 
previous studies, triple antiplatelet therapy was shown to be 
more effective after PCI for preventing stent thrombosis or ma-
jor cardiovascular events than dual antiplatelet therapy.
6-11) Cur-
rently, it is not clear whether triple therapy induces bleeding 
more frequently than dual therapy.
12) For recurrent stent throm-
bosis, oral anticoagulation can be considered as an option,
13)14) 
although there is controversy regarding the value of warfarin 
administration after PCI. When oral anticoagulation is con-
sidered in patients with stent thrombosis, the risk of bleeding 
is a major concern.
13)15) One recent study reported that antico-
agulant therapy did not increase the risk of major bleeding 
in patients with atrial fibrillation undergoing PCI.
15) However, 
some studies suggest that warfarin increases the risk of major 
bleeding when added to antiplatelet therapy.
5) Although war-
farin in combination with antiplatelet therapy may be an op-
tion for treating stent thrombosis, oral anticoagulation for the 
prevention of stent thrombosis needs to be individualized. Par-
ticularly, the bleeding risk of each patient should be carefully 
assessed before treatment. 
Our patient suffered from massive renal hemorrhage that 
resulted in death. He had risk factors for bleeding such as end-
stage renal disease and concomitant triple antiplatelet thera-
py plus oral anticoagulation.
4)5) Moreover, PKD is known as a 
cause of recurrent hematuria and renal hemorrhage.
16) Because 
renal cysts are prone to rupture after even light trauma, a poly-
cystic kidney can be a major source of bleeding. 
A thorough evaluation of the bleeding risks of PKD before 
the implementation of aggressive antithrombotic therapy 
could have been helpful in our patient. Major bleeding can 
be disastrous in coronary artery disease patients for several 
reasons. Heart function is decreased in many coronary artery 
disease patients and patients are more likely to have comor-
bidities such as hypertension, diabetes, and renal insufficien-
cy. Compensatory elevation of heart rate in response to hypo-
volemia can be masked in patients who are taking beta blockers. 
As a result, early detection of bleeding can be difficult. There-
fore, every effort should be made to detect any symptoms or 
signs of bleeding in these patients. 
In conclusion, although aggressive antithrombotic therapy 
can be considered an option for treatment of recurrent stent 
thrombosis, the patient’s risk of bleeding should be evaluated 
thoroughly. The risks and benefits of triple antiplatelet therapy 
plus additional oral anticoagulation must be taken into account. 
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